Company intelligence / Profile preview
Ubix Therapeutics
Seoul, Seoul, South Koreaubixtrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ubix Therapeutics is developing UBX-103, an AR degrader with picomolar DC50 that shows efficacy against treatment-induced resistance mutations and inhibits growth of tumors resistant to next-generation hormonal therapy in preclinical models. The company recently entered a license agreement with Yuhan for this program.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculestargeted protein degraders
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
YuhanSK Biopharmaceuticals
Beyond the preview
Go deeper on Ubix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ubix Therapeutics.